THC in Chronic Pain Management

Chemical Identity and Mechanism

The primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (THC), acts as a partial agonist at cannabinoid receptor Type 1 (CB1) and Type 2 (CB2) receptors, which are targets for pain pathway modulation, according to the British Journal of Anaesthesia 1, 2
THC concentrations in the cannabis plant have increased from 9% in 2008 to 17% in 2017, with some concentrates reaching 70% THC, as reported by the Annals of Internal Medicine 3
Under federal law, cannabis products containing more than 0.3% THC are classified as marijuana, while those with ≤0.3% THC are classified as hemp, as stated by the Annals of Internal Medicine 3

Two randomized controlled trials in HIV-associated neuropathic pain demonstrated that smoked cannabis containing 3.56-8% THC provided statistically significant pain reduction compared to placebo, with 46-52% of patients achieving >30% pain reduction, as found by Clinical Infectious Diseases 4, 5
Pain was reduced by 34% in the THC group versus 17% in placebo (P = 0.03) in one trial, according to Clinical Infectious Diseases 4, 5
The CB1 receptor is found in virtually all CNS tissues and represents the primary target for THC's analgesic effects in pain pathways, as reported by the British Journal of Anaesthesia 1, 2

THC produces psychoactive effects including euphoria, which distinguishes it from CBD, though CBD does produce other psychoactive effects without euphoria, as stated by the Annals of Internal Medicine and the British Journal of Anaesthesia 3, 1
A typical cannabis cigarette contains 500-750 mg of plant material, with actual THC delivery varying based on concentration, smoking technique, and inspiratory effort, as reported by the British Journal of Anaesthesia 1, 6
Clinical trials have used THC doses ranging from 2.5 mg twice daily to 5 mg three times daily for pain management, according to Clinical Nutrition and Clinical Infectious Diseases 4, 5, 7

One patient without prior cannabis exposure developed acute psychosis during a clinical trial and required study discontinuation, as reported by Clinical Infectious Diseases 4, 5
High doses of THC may be associated with psychosis, particularly in cannabis-naive patients, as stated by the Annals of Internal Medicine 3
THC causes beta-adrenergic-mediated tachycardia and may increase myocardial ischemia risk in susceptible individuals, as reported by the British Journal of Anaesthesia 1, 6, 8
Cardiovascular effects include elevated heart rate, blood pressure, and potential arrhythmias, with one Danish study showing increased 180-day new-onset arrhythmia risk, as stated by the Annals of Internal Medicine 3

The American College of Oncology suggests that THC functions as a partial agonist at CB1 and CB2 cannabinoid receptors, which are key modulators of immune system activity and inflammatory pathways, affecting T-cell proliferation, activation, and cytotoxic activity; granulocyte cytokine production; dendritic and natural killer cell function; and neutrophil chemotactic capacity 9
The European Society of Gastroenterology indicates that CB1 receptors are densely distributed in brain regions controlling inflammation, while CB2 receptors are primarily located on immune and inflammatory cells 10

The American Society of Clinical Oncology recommends that cannabis consumption be avoided during cancer immunotherapy treatment, as it decreases response rates to nivolumab and significantly decreases time to tumor progression and overall survival in patients receiving immunotherapy 9
The American College of Oncology states that THC directly reduces the therapeutic effect of PD-1 blockade by suppressing T-cell antitumor immunity through inhibition of JAK/STAT signaling via cannabinoid receptor type 2 9
The National Comprehensive Cancer Network notes that even the endogenous cannabinoid anandamide impedes antitumor immunity, indicating an immunosuppressive role of the entire endocannabinoid system 9

The American Academy of Pain Medicine suggests that in conditions characterized by excessive inflammation without need for active immune surveillance, THC's anti-inflammatory properties could theoretically provide benefit 9
The American Society of Clinical Oncology advises that during immunotherapy, cannabis should be avoided entirely, as the same anti-inflammatory mechanism that may reduce pain becomes dangerous when immune activation is therapeutically necessary 9